Skip to main content
Top
Published in: Drugs & Aging 5/2014

01-05-2014 | Review Article

Pharmacologic Options in the Management of Upper Gastrointestinal Bleeding: Focus on the Elderly

Authors: Moe Htet Kyaw, Francis Ka Leung Chan

Published in: Drugs & Aging | Issue 5/2014

Login to get access

Abstract

Despite the major advances in the treatment of peptic ulcer disease, its complication in the elderly has increased. This is because of the increasing use of non-steroidal anti-inflammatory drugs, and the high prevalence of Helicobacter pylori infection. The presentation of peptic ulcers in the elderly patients can be subtle, and late presentation with upper gastrointestinal bleeding of peptic ulcers is not uncommon in the elderly population. The aim of this article is to review the current treatment options for upper gastrointestinal bleeding, and to discuss the place of drug therapy in both the acute and ongoing management of individual patients. Its focus will be on the benefits and risks of each option in the elderly. There is significant evidence to suggest that anti-secretory medications are useful in the treatment of peptic ulcers and associated complications in the elderly. Although a large number of studies have reported potential adverse effects of proton pump inhibitors, this evidence comes from retrospective observational studies, and such reports should be regarded with caution, and randomized controlled studies are required to confirm or refute these results. Nonetheless, it will be important to practice the appropriate use of acid suppression therapy, and identify which patients will gain maximum benefit from proton pump inhibitor therapy.
Literature
1.
go back to reference Bardhan KD, Cust G, Hinchliffe RF, et al. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg. 1989;76:230–6.PubMedCrossRef Bardhan KD, Cust G, Hinchliffe RF, et al. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg. 1989;76:230–6.PubMedCrossRef
2.
go back to reference Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–4.PubMedCentralPubMedCrossRef Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–4.PubMedCentralPubMedCrossRef
4.
go back to reference Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med. 1992;116:636–40.PubMedCrossRef Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med. 1992;116:636–40.PubMedCrossRef
5.
go back to reference Goto H, Sugiyama S, Ohara A, et al. Age-associated decreases in prostaglandin contents in human gastric mucosa. Biochem Biophys Res Commun. 1992;186:1443–8.PubMedCrossRef Goto H, Sugiyama S, Ohara A, et al. Age-associated decreases in prostaglandin contents in human gastric mucosa. Biochem Biophys Res Commun. 1992;186:1443–8.PubMedCrossRef
6.
go back to reference Guslandi M, Pellegrini A, Sorghi M. Gastric mucosal defences in the elderly. Gerontology. 1999;45:206–8.PubMedCrossRef Guslandi M, Pellegrini A, Sorghi M. Gastric mucosal defences in the elderly. Gerontology. 1999;45:206–8.PubMedCrossRef
7.
go back to reference Kim SW, Parekh D, Townsend CM, Jr, et al. Effects of aging on duodenal bicarbonate secretion. Ann Surg. 1990;212:332–7 (discussion 337–8). Kim SW, Parekh D, Townsend CM, Jr, et al. Effects of aging on duodenal bicarbonate secretion. Ann Surg. 1990;212:332–7 (discussion 337–8).
8.
go back to reference Brogna A, Ferrara R, Bucceri AM, et al. Influence of aging on gastrointestinal transit time: an ultrasonographic and radiologic study. Invest Radiol. 1999;34:357–9.PubMedCrossRef Brogna A, Ferrara R, Bucceri AM, et al. Influence of aging on gastrointestinal transit time: an ultrasonographic and radiologic study. Invest Radiol. 1999;34:357–9.PubMedCrossRef
9.
go back to reference Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222–6.PubMedCentralPubMedCrossRef Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222–6.PubMedCentralPubMedCrossRef
10.
11.
go back to reference Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology. 1997;43:283–8.PubMedCrossRef Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology. 1997;43:283–8.PubMedCrossRef
12.
go back to reference Pilotto A, Maggi S, Noale M, et al. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci. 2010;65:174–8.PubMedCrossRef Pilotto A, Maggi S, Noale M, et al. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci. 2010;65:174–8.PubMedCrossRef
13.
go back to reference de Manzoni G, Catalano F, Festini M, et al. Acute hemorrhage caused by duodenal ulcer: results of endoscopic treatment of the first bleeding episode and of recurrences. Ann Ital Chir. 2002;73:387–94 (discussion 394–6). de Manzoni G, Catalano F, Festini M, et al. Acute hemorrhage caused by duodenal ulcer: results of endoscopic treatment of the first bleeding episode and of recurrences. Ann Ital Chir. 2002;73:387–94 (discussion 394–6).
14.
go back to reference Carbonell N, Pauwels A, Serfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006;101:1211–5.PubMedCrossRef Carbonell N, Pauwels A, Serfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006;101:1211–5.PubMedCrossRef
15.
go back to reference Coffin B, Pocard M, Panis Y, et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc. 2002;56:174–9.PubMedCrossRef Coffin B, Pocard M, Panis Y, et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc. 2002;56:174–9.PubMedCrossRef
16.
go back to reference Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology. 2002;123:17–23.PubMedCrossRef Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology. 2002;123:17–23.PubMedCrossRef
17.
go back to reference Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc. 2010;72:1138–45.PubMedCrossRef Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc. 2010;72:1138–45.PubMedCrossRef
18.
go back to reference Pateron D, Vicaut E, Debuc E, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011;57:582–9.PubMedCrossRef Pateron D, Vicaut E, Debuc E, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011;57:582–9.PubMedCrossRef
19.
go back to reference Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356:1631–40.PubMedCrossRef Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356:1631–40.PubMedCrossRef
20.
go back to reference Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415.
21.
go back to reference Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33–47 (quiz 1–2). Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33–47 (quiz 1–2).
22.
go back to reference Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;6:CD007999. Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;6:CD007999.
23.
go back to reference Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther. 2013;38:721–8.PubMedCrossRef Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther. 2013;38:721–8.PubMedCrossRef
25.
go back to reference Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs: Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991;337:85–9.PubMedCrossRef Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs: Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991;337:85–9.PubMedCrossRef
26.
go back to reference Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol. 2002;53:183–8.PubMedCentralPubMedCrossRef Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol. 2002;53:183–8.PubMedCentralPubMedCrossRef
27.
go back to reference Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–10.PubMedCrossRef Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–10.PubMedCrossRef
28.
go back to reference Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.PubMedCrossRef Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.PubMedCrossRef
29.
go back to reference Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60:1170–7.PubMedCrossRef Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60:1170–7.PubMedCrossRef
30.
go back to reference Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.PubMedCrossRef Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.PubMedCrossRef
31.
go back to reference Lau JY, Barkun A, Fan DM, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381:2033–43.PubMedCrossRef Lau JY, Barkun A, Fan DM, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381:2033–43.PubMedCrossRef
32.
go back to reference Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–54.PubMedCrossRef Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–54.PubMedCrossRef
33.
go back to reference Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20:1091–7.PubMedCrossRef Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20:1091–7.PubMedCrossRef
34.
go back to reference Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30:43–7.PubMed Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30:43–7.PubMed
35.
go back to reference Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–35.PubMedCentralPubMedCrossRef Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–35.PubMedCentralPubMedCrossRef
36.
go back to reference Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701–10.PubMedCrossRef Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701–10.PubMedCrossRef
37.
go back to reference Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.
38.
go back to reference Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–26.PubMedCrossRef Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–26.PubMedCrossRef
39.
go back to reference Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.PubMedCrossRef Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.PubMedCrossRef
40.
go back to reference Stupnicki T, Dietrich K, Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion. 2003;68:198–208.PubMedCrossRef Stupnicki T, Dietrich K, Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion. 2003;68:198–208.PubMedCrossRef
41.
go back to reference Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–8.PubMedCrossRef Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–8.PubMedCrossRef
42.
go back to reference Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.PubMedCrossRef Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.PubMedCrossRef
43.
go back to reference Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82–8.PubMedCrossRef Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82–8.PubMedCrossRef
44.
go back to reference Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–44.PubMedCrossRef Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–44.PubMedCrossRef
45.
go back to reference Wang X, Tian HJ, Yang HK, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23:876–80.PubMedCrossRef Wang X, Tian HJ, Yang HK, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23:876–80.PubMedCrossRef
46.
go back to reference Pilotto A. Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies. Drugs Aging. 2001;18:487–94.PubMedCrossRef Pilotto A. Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies. Drugs Aging. 2001;18:487–94.PubMedCrossRef
47.
go back to reference Pilotto A, Franceschi M, Di Mario F, et al. The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease. Gerontology. 1998;44:153–8.PubMedCrossRef Pilotto A, Franceschi M, Di Mario F, et al. The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease. Gerontology. 1998;44:153–8.PubMedCrossRef
48.
go back to reference Salles N, Megraud F. Current management of Helicobacter pylori infections in the elderly. Expert Rev Anti Infect Ther. 2007;5:845–56.PubMedCrossRef Salles N, Megraud F. Current management of Helicobacter pylori infections in the elderly. Expert Rev Anti Infect Ther. 2007;5:845–56.PubMedCrossRef
49.
go back to reference Pilotto A, Franceschi M, Leandro G, et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Aliment Pharmacol Ther. 2001;15:1031–6.PubMedCrossRef Pilotto A, Franceschi M, Leandro G, et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Aliment Pharmacol Ther. 2001;15:1031–6.PubMedCrossRef
50.
go back to reference Pilotto A, Franceschi M, Perri F, et al. Treatment options for Helicobacter pylori infection in the elderly. Aging Health. 2006;2:661.CrossRef Pilotto A, Franceschi M, Perri F, et al. Treatment options for Helicobacter pylori infection in the elderly. Aging Health. 2006;2:661.CrossRef
51.
go back to reference Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMedCrossRef Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMedCrossRef
52.
go back to reference Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159:2312–6.PubMed Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159:2312–6.PubMed
53.
go back to reference Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol. 2002;444:209–15.PubMedCrossRef Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol. 2002;444:209–15.PubMedCrossRef
54.
go back to reference Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care. 2000;6:S491–505.PubMed Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care. 2000;6:S491–505.PubMed
55.
go back to reference Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173:518–23.PubMedCrossRef Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173:518–23.PubMedCrossRef
56.
go back to reference Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–9.PubMedCrossRef Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–9.PubMedCrossRef
57.
go back to reference Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–11.PubMedCrossRef Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–11.PubMedCrossRef
58.
go back to reference Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–6.PubMed Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–6.PubMed
59.
go back to reference Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3–10.PubMedCrossRef Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3–10.PubMedCrossRef
60.
go back to reference Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56 (quiz 2057). Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56 (quiz 2057).
61.
go back to reference Janarthanan S, Ditah I, Kutait A. A meta-analysis of 16 observational studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J Gastroenterol. 2010;105:S139.CrossRef Janarthanan S, Ditah I, Kutait A. A meta-analysis of 16 observational studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J Gastroenterol. 2010;105:S139.CrossRef
62.
go back to reference Shukla S, Shukla A, Guha S. Use of proton pump inhibitors and risk of Clostridium difficile-associated diarrhea: a meta-analysis. Gastroenterology. 2010;138:209. Shukla S, Shukla A, Guha S. Use of proton pump inhibitors and risk of Clostridium difficile-associated diarrhea: a meta-analysis. Gastroenterology. 2010;138:209.
63.
go back to reference Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:225–33.PubMedCrossRef Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:225–33.PubMedCrossRef
65.
go back to reference Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–9.PubMedCentralPubMedCrossRef Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–9.PubMedCentralPubMedCrossRef
66.
go back to reference Altman KW, Waltonen JD, Hammer ND, et al. Proton pump (H+/K+-ATPase) expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg. 2005;133:718–24.PubMedCrossRef Altman KW, Waltonen JD, Hammer ND, et al. Proton pump (H+/K+-ATPase) expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg. 2005;133:718–24.PubMedCrossRef
67.
go back to reference Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31:1165–77.PubMedCrossRef Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31:1165–77.PubMedCrossRef
68.
69.
go back to reference Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–44.PubMedCrossRef Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–44.PubMedCrossRef
70.
go back to reference O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.PubMedCrossRef O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.PubMedCrossRef
71.
go back to reference Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.PubMedCrossRef Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.PubMedCrossRef
72.
go back to reference Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18 (quiz 1219). Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18 (quiz 1219).
73.
go back to reference Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768–76.PubMedCrossRef Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768–76.PubMedCrossRef
74.
go back to reference Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794–800.PubMedCrossRef Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794–800.PubMedCrossRef
75.
go back to reference Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013;12:709–16.PubMedCrossRef Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013;12:709–16.PubMedCrossRef
76.
go back to reference Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288–92.PubMedCrossRef Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288–92.PubMedCrossRef
77.
78.
go back to reference Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–91.PubMedCrossRef Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–91.PubMedCrossRef
79.
go back to reference Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120:211–5.PubMedCrossRef Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120:211–5.PubMedCrossRef
80.
go back to reference Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110–21.PubMedCrossRef Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110–21.PubMedCrossRef
81.
go back to reference Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162–7.PubMedCrossRef Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162–7.PubMedCrossRef
82.
go back to reference Dharmarajan TS, Norkus EP. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? Nat Clin Pract Gastroenterol Hepatol. 2008;5:604–5.PubMedCrossRef Dharmarajan TS, Norkus EP. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? Nat Clin Pract Gastroenterol Hepatol. 2008;5:604–5.PubMedCrossRef
83.
go back to reference Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996;275:308–14.PubMedCrossRef Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996;275:308–14.PubMedCrossRef
84.
go back to reference Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321:1103–6.PubMedCentralPubMedCrossRef Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321:1103–6.PubMedCentralPubMedCrossRef
86.
go back to reference Ornstein SM, Nietert PJ, Jenkins RG, et al. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med. 2013;26:518–24.PubMedCrossRef Ornstein SM, Nietert PJ, Jenkins RG, et al. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med. 2013;26:518–24.PubMedCrossRef
87.
go back to reference Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84.PubMedCrossRef Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84.PubMedCrossRef
88.
go back to reference Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28:509–18.PubMedCrossRef Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28:509–18.PubMedCrossRef
91.
go back to reference Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.PubMedCentralPubMedCrossRef Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.PubMedCentralPubMedCrossRef
92.
go back to reference Simonson W, Feinberg JL. Medication-related problems in the elderly: defining the issues and identifying solutions. Drugs Aging. 2005;22:559–69.PubMedCrossRef Simonson W, Feinberg JL. Medication-related problems in the elderly: defining the issues and identifying solutions. Drugs Aging. 2005;22:559–69.PubMedCrossRef
Metadata
Title
Pharmacologic Options in the Management of Upper Gastrointestinal Bleeding: Focus on the Elderly
Authors
Moe Htet Kyaw
Francis Ka Leung Chan
Publication date
01-05-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0173-5

Other articles of this Issue 5/2014

Drugs & Aging 5/2014 Go to the issue